Psychiatr. praxi 2018; 19(1): 7-10 | DOI: 10.36290/psy.2018.002
Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia
- Oddělení klinické farmacie, Ústavní lékárna IKEM, Praha
Alzheimer disease is the most prevalent cause of dementia. A precise diagnosis is required for effective management. Cholinesteraseinhibitors are used as first line therapy to provide modest symptomatic benefit in some patients, memantine appears tohave modest benefits in patients with moderate to severe disease. Neuropsychiatric symptoms are common in dementia andcontribute to nursing home admission and caregiver stress. Identifying the genesis of the abnormal behavior is critical, in orderthat nonpharmacologic therapies are preferred over medication. Symptomatic pharmacologic treatment includes antidepressants,antipsychotics, anxiolytics and other alternatives. The following review discusses risks and benefits of particular drugs.
Keywords: Alzheimer, dementia, cholinesterase inhibitors, memantine, antidepressants, antipsychotics
Published: April 10, 2018 Show citation
References
- Mátl O, et al. Zpráva o stavu demence 2016. Česká alzheimerovská společnost, o. p. s., ISBN 978-80-86541-50-1, 2016, Dostupný z: http://www.alzheimer.cz/res/archive/004/000480.pdf?seek=1492589048.
- Holmerová I, et al. Rizika a nevýhody podávání antipsychotik v dlouhodobé péči u pacientů s demencí. Psychiatr. praxi 2014; 15(2): 58-61.
- Vyhnálek M, et al. Diagnostikujeme a léčíme demence správně a včas? Výsledky průzkumu ve světle nových doporučení. Neurol. praxi 2011; 12(5): 352-358.
- Sheardová K, et al. Doporučené postupy pro terapii Alzheimerovy nemoci a ostatních demencí. Neurol. pro praxi 2009; 10(1): 28-31.
- Česká lékárnická komora. Poradenství a péče o pacienty s Alzheimerovou chorobou. [Online] [Cit. dne: 4.12.2017] Dostupný z: https://www.lekarnici.cz/Pro-verejnost/Odborne-poradenstvi-v-lekarnach/Poradenstvi-a-pece-o-pacienty-s%C2%A0Alzheimerovou-chor.aspx
- Jirák R. Alzheimerova choroba. In: Raboch et al. Doporučené postupy psychiatrické péče IV. Psychiatrická společnost ČLS JEP, 2014, ISBN 978-80-260-5792-5.
- Press D, Alexander M. Treatment of dementia. Databáze UpToDate. [Online] [Cit. dne: 6.12.2017].
- Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. Databáze UpToDate. [Online] [Cit. dne: 4.12.2017].
- Doody, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58(3): 427-433.
Go to original source... 
Go to PubMed... - Small, et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59(4): 473-477. Go to original source... Go to PubMed...
- Farlow, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 2010; 32: 1234. Go to original source... Go to PubMed...
- Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract 2002; Suppl 127: 45-63.
- Brunovský M. Inhibitory cholinesteráz v léčbě Alzheimerovy nemoci. Neurol. pro praxi 2007; 2: 112-117.
- Reisberg, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63(1): 49-54. Go to original source... Go to PubMed...
- Howard, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 893-903. Go to original source... Go to PubMed...
- Howard, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol 2015; 14(12): 1171-1181. Go to original source... Go to PubMed...